Merck & Co. Inc. and Aetna Inc. have signed a value-based reimbursement agreement for the DPP-4 medications Januvia (sitagliptin) and Janumet (sitagliptin/metformin) for the treatment of type 2 diabetes, linking the cost of the medicines to intensification of treatment rather than a health outcome like reduction in hemoglobin A1C.
Under the agreement announced Oct. 11, Merck would pay larger rebates for Januvia and Janumet if patients need to add...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?